Investigating how neprilysin inhibition affects heart tissue fibrosis
Official title: Effect of Neprilysin Inhibition on Myocardial Interstitial Fibrosis
Funded at Brigham and Women's Hospital · NIH-10801055 · Data updated 2026-11-12
This study is looking at how certain changes in heart tissue might affect people with heart failure and aims to find new treatment options by exploring the impact of a specific medication on heart health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $195,480 |
| NIH project number | 1K23HL168163-01A1 |
| Project ID | NIH-10801055 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with heart failure with preserved ejection fraction, particularly those with underlying conditions like hypertension or diabetes.
✕Less likely to help
Patients who do not have heart failure or those with heart failure with reduced ejection fraction may not benefit from this research.
What this research studies
This research focuses on heart failure with preserved ejection fraction (HFpEF), a condition affecting millions of Americans. It aims to understand how myocardial interstitial fibrosis (MIF), which is caused by factors like hypertension and diabetes, contributes to HFpEF. The study will utilize advanced techniques such as cardiac MRI and large-scale proteomics to explore the effects of neprilysin inhibition on the extracellular matrix in heart tissue. By examining the relationship between neprilysin inhibition and levels of regulatory proteins, the research seeks to identify potential new treatments for this challenging condition.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively treat or prevent heart failure with preserved ejection fraction.
How similar studies have gone: Previous research has shown promising results with neprilysin inhibition in heart failure treatments, indicating potential for success in this novel approach.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Cunningham, Jonathan Woo — Brigham and Women's Hospital
- Study coordinator: Cunningham, Jonathan Woo
Related research
Other NIH-funded projects on the same topics.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
-
Metabolic changes in cells that repair blood vessels in the eye lens to prevent scarring
A drug or approach that changes how certain cells that repair blood vessels in the eye work, to prevent scarring behind the retina in age-related macular degeneration patients treated with anti-VEGF therapy.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.